Sino Biopharmaceutical is a leading Chinese innovative research and R&D-driven pharmaceutical group
Sino Biopharmaceutical, founded in 2020 and headquartered in Hong Kong, is the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the entire industry chain of pharmaceutical R&D platforms, intelligent production, and strong sales systems. Established by Xie Qirun, it was listed on the Hong Kong Stock Exchange In September of the same year as the foundation. The company's major shareholders are Thousand Eagles Limited, FRANCE INVESTMENT (CHINA 1) GROUP LIMITED, Remarkable Industries Limited, and Validated Profits Limited. Rivals with the direct and indirect competition with Sino Biopharmaceutical include Lansen Pharmaceutical, Chia Tai Enterprises, Hansoh Pharma.
Analysis of In Vitro Diagnostics Industry in China
It has been almost three years since the coronavirus outbreak. In the post-Covid era, PCR tests and antigen reagents have become part of daily essentials. The increasing demand for PCR tests drives the development of IVD in China. What is IVD? How to explain its popularity in China over the past two or three years? You will find all the answers above in this article.
Aug 23, 2022 12:15 PM
ResearchTechnology, Healthcare, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchHealthcare, Real Estate, Industrials
Tech for Global, Globalization Footprints of the Established and the New
Ubrigene Bags Hundreds of Mns of CNY in Series C Financing Round
Ubrigene, dedicated to providing one-stop CDMO services for cell and gene therapies, will continue to improve its management system and incubate more specialized technology platforms with the fresh proceeds.
Sep 27, 2022 06:35 PM
Blood Cancer, ‘Bloody Invisible Invader’ in China
Blood cancers including leukemia, lymphoma and myeloma are the top 10 cancer diseases worldwide. However, due to their distinct features from solid cancers, the diagnosis of them is much more challenging and requires extra care. Patients possessing blood cancers often have less awareness and blood cancers can be a so-called the invisible invader. This article gives an introduction to blood cancers then generally dissects what challenges the industry is facing in China.
Sep 22, 2022 11:09 AM
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM